Figure 1
From: Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma
Kaplan–Meier survival curves for PFS (left) and OS (right) depending on pathway mutation at next-generation sequencing analysis.
Figure 1 | Scientific Reports
